Histamine H3 and H4 receptors as novel drug targets

Expert Opinion on Investigational Drugs

Volumn 18, Issue 10, 2009, Pages 1519-1531

  Tiligada, Ekaterini ^a   Zampeli, Evangelia ^a   Sander, Kerstin ^b   Stark, Holger ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Allergy; Arthritis; Attention deficit hyperactivity disorder; Autoimmune disorders; Cancer; Cognitive impairment; Drug target; Epilepsy; H3R; H4R; Histamine; Inflammation; Neuronal diseases; Pain; Schizophrenia; Sleep wake

Indexed keywords

1 (5 CHLORO 2 INDOLYLCARBONYL) 4 METHYLPIPERAZINE; 1 [2 (AMIDINOTHIO)ETHYL]GUANIDINE; 5 (4 CYANOPHENYL) 2 [2 (2 METHYL 1 IMIDAZOLIDINYL)ETHYL]BENZOFURAN; A 943931; A 987306; BP [2-94]; CIPROXIFAN; CLOBENPROPIT; DULOXETINE; GABAPENTIN; GSK 1004723; GSK 189254; GSK 207040; GSK 239512; GSK 334429; GSK 835726; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR ANTAGONIST; HISTAMINE H4 RECEPTOR; IMETIT; IMMEPIP; JNJ 17216498; JNJ 5207852; JNJ 6379490; PF 03654746; PHENYTOIN; PLACEBO; THIOPERAMIDE; TIPROLISANT; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTIHISTAMINIC AGENT; G PROTEIN COUPLED RECEPTOR; HISTAMINE RECEPTOR; HRH4 PROTEIN, HUMAN;

ALLERGIC RHINITIS; ALLERGY; ASTHMA; ATTENTION DEFICIT DISORDER; CHEMICAL STRUCTURE; CLINICAL TRIAL; COGNITIVE DEFECT; COLON CARCINOMA; DEMENTIA; EPILEPSY; HUMAN; NARCOLEPSY; NEUROPATHIC PAIN; NONHUMAN; OSTEOARTHRITIS; PARKINSON DISEASE; REVIEW; RHEUMATOID ARTHRITIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SKIN INFLAMMATION; SKIN PRURITUS; SLEEP DISORDER; TEMPORAL LOBE EPILEPSY; ANIMAL; DRUG DELIVERY SYSTEM; DRUG EFFECT; IMMUNOPATHOLOGY; INFLAMMATION; INVERSE AGONISM; METABOLISM; NEUROLOGIC DISEASE; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL;

ANIMALS; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG INVERSE AGONISM; HISTAMINE ANTAGONISTS; HUMANS; IMMUNE SYSTEM DISEASES; INFLAMMATION; NERVOUS SYSTEM DISEASES; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, HISTAMINE; RECEPTORS, HISTAMINE H3;

EID: 70349330821     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728220903188438     Document Type: Review

References (99)

1. Lim HD, van Rijn RM, Ling P, et al. Evaluation of histamine H1-, H2-, and H3- receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist. J Pharmacol Exp Ther 2005;314:1310-1321 • Evaluation of H4R for its interaction with various known histaminergic ligands and identification of 4-methylhistamine as a potent H4R agonist.
2. Pollard H, Moreau J, Arrang JM, Schwartz JC. A detailed autoradiographic mapping of histamine H3 receptors in rat brain areas. Neuroscience 1993;52:169-189 (Pubitemid 23026616)
3. Bertaccini G, Coruzzi G, Adami M, et al. Histamine H3 receptors: an overview. Ital J Gastroenterol 1991;23:378-385
4. Arrang JM, Garbarg M, Schwartz JC. Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 1983;302:832-837
5. Arrang JM, Morisset S, Gbahou F. Constitutive activity of the histamine H3 receptor. Trends Pharmacol Sci 2007;28:350-357 • Concise review on constitutive activity and efficacies of reference structures.
6. Sander K, Kottke T, Stark H. Histamine H3 receptor antagonists go to clinics. Biol Pharm Bull 2008;31:2163-2181 • Recent review covering the latest findings relating to H3R pharmacology and detailed structure-affinity relationships.
7. Celanire S, Lebon F, Stark H. Drug discovery: from hits to clinical candidates. In: Vohora DS, editor, The third histamine receptor: selective ligands as potential therapeutic agents in CNS disorders.: Taylor & Francis CRC Press, Inc., Boca Raton, FL, USA 2008
8. Ligneau X, Morisset S, Tardivel-Lacombe J, et al. Distinct pharmacology of rat and human histamine H3 receptors: role of two amino acids in the third transmembrane domain. Br J Pharmacol 2000;131:1247-1250
9. Strakhova MI, Fox GB, Carr TL, et al. Cloning and characterization of the monkey histamine H3 receptor isoforms. Eur J Pharmacol 2008;601:8-15
10. Bakker RA. Histamine H3 receptor isoforms. Inflamm Res 2004;53:509-516
11. Fernandez-Novoa L, Cacabelos R. Histamine function in brain disorders. Behav Brain Res 2001;124:213-233
12. Alvarez EO. The role of histamine on cognition. Behav Brain Res 2009;199:183-189 • Topical review about the histaminergic system in cognition.
13. Munari L, Passani MB, Benetti F, et al. ABT-239, an H3 receptor antagonist, reveals heterogeneity among histaminergic neurons. XXXVIIIth Meeting of the European Histamine Research Society. Fulda, Germany 13 - 16 May 2009 O3
14. Blandina P, Efoudebe M, Cenni G, et al. Acetylcholine, histamine, and cognition: two sides of the same coin. Learn Mem 2004;11:1-8 (Pubitemid 38167052)
15. Passani MB, Blandina P. The neuronal histaminergic system in cognition. Curr Med Chem Cent Nerv Syst Agents 2004;4:17-26
16. Bacciottini L, Passani MB, Mannaioni PF, Blandina P. Interactions between histaminergic and cholinergic systems in learning and memory. Behav Brain Res 2001;124:183-194 (Pubitemid 32964637)
17. Fox GB, Esbenshade TA, Pan JB, et al. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl] ethyl}-benzofuran-5-yl) benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist. J Pharmacol Exp Ther 2005;313:176-190 (Pubitemid 40411341)
18. Bonaventure P, Letavic M, Dugovic C, et al. Histamine H3 receptor antagonists: from target identification to drug leads. Biochem Pharmacol 2007;73:1084-1096 • Preclinical investigations on diamine-containing H3R ligands by Johnson & Johnson. (Pubitemid 46413171)
19. GSK-pipeline. 2009. Available from: http://www.gsk.com/investors/product- pipeline/docs/gsk-pipeline-feb09.pdf
20. An imaging study to investigate the distribution of GSK 239512 in the brain. Available from: http://www.clinicaltrials.gov
21. Drahl C. Curtain rises on potential drugs. ACS meeting news: medicinal chemists disclose candidates for treating neurological, metabolic, and other disorders. Chem Eng News 2009;87:31-33
22. Humbert-Claude M, Morisset S, Gbahou F, Arrang JM. Histamine H3 and dopamine D2 receptor-mediated [35S] GTPgamma[S] binding in rat striatum: evidence for additive effects but lack of interactions. Biochem Pharmacol 2007;73:1172-1181
23. Ferrada C, Ferre S, Casado V, et al. Interactions between histamine H3 and dopamine D2 receptors and the implications for striatal function. Neuropharmacology 2008;55:190-197
24. Ferrada C, Moreno E, Casado V, et al. Marked changes in signal transduction upon heteromerization of dopamine D1 and histamine H3 receptors. Br J Pharmacol 2009;157:64-75 • H3R heterodimerization and functional characterization.
25. Jin CY, Anichtchik O, Panula P. Altered histamine H3 receptor radioligand binding in post-mortem brain samples from subjects with psychiatric diseases. Br J Pharmacol 2009;157:118-129
26. Pietro NCD, Seamans JK. Dopamine and serotonin interactions in the prefrontal cortex: insights on antipsychotic drugs and their mechanism of action. Pharmacopsychiatry 2007;40:S27-33
27. Morisset S, Sahm UG, Traiffort E, et al. Atypical neuroleptics enhance histamine turnover in brain via 5-hydroxytryptamine2A receptor blockade. J Pharmacol Exp Ther 1999;288:590-596 (Pubitemid 29119669)
28. Southam E, Cilia J, Gartlon JE, et al. Preclinical investigations into the antipsychotic potential of the novel histamine H3 receptor antagonist GSK 207040. Psychopharmacol 2009;201:483-494
29. Ligneau X, Landais L, Perrin D, et al. Brain histamine and schizophrenia: potential therapeutic applications of H3 receptor inverse agonists studied with BF2.649. Biochem Pharmacol 2007;73:1215-1224 (Pubitemid 46420689)
30. Ferrer International S.A. Monohydrochloride salt of 1-[3-[3-(4- chlorophenyl) propoxy]propyl]-piperidine. WO2006084833A1; 2006 • Patent application containing data of human pilot studies with tiprolisant. 31. A randomized, double blind, placebo controlled, study to demonstrate the cognitive enhancing effects of BF2.649 in people with schizophrenia and schizoaffective disorder. Available from: http://www.clinicaltrials.gov
31. von Coburg Y, Kottke T, Weizel L, et al. Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics. Bioorg Med Chem Lett 2009;19:538-542
32. Ito C. Histamine H3 receptor inverse agonists as novel antipsychotics. Cent Nerv Syst Agents Med Chem 2009;9:132-136
33. Stevens DR, Eriksson KS, Brown RE, Haas HL. The mechanism of spontaneous firing in histamine neurons. Behav Brain Res 2001;124:105-112
34. Jones BE. From waking to sleeping: neuronal and chemical substrates. Trends Pharmacol Sci 2005;26:578-586
35. Saras A, Gisselmann G, Vogt-Eisele AK, et al. Histamine action on vertebrate GABAA receptors: direct channel gating and potentiation of GABA responses. J Biol Chem 2008;283:10470-10475
36. Brown RE, Sergeeva OA, Eriksson KS, Haas HL. Convergent excitation of dorsal raphe serotonin neurons by multiple arousal systems (orexin/hypocretin, histamine and noradrenaline). J Neurosci 2002;22:8850-8859
37. Hong ZY, Huang ZL, Qu WM, Eguchi N. Orexin A promotes histamine, but not norepinephrine or serotonin, release in frontal cortex of mice. Acta Pharmacol Sin 2005;26:155-159 (Pubitemid 40203958)
38. Huang ZL, Qu WM, Li WD, et al. Arousal effect of orexin A depends on activation of the histaminergic system. Proc Natl Acad Sci USA 2001;98:9965-9970
39. Stevens DR, Kuramasu A, Haas HL. GABAB receptor-mediated control of GABAergic inhibition in rat histaminergic neurons in vitro. Eur J Neurosci 1999;11:1148-1154 (Pubitemid 29142175)
40. Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet 2007;369:499-511
41. John J, Wu MF, Boehmer LN, Siegel JM. Cataplexy-active neurons in the hypothalamus: implications for the role of histamine in sleep and waking behavior. Neuron 2004;42:619-634 (Pubitemid 38639881)
42. Parmentier R, Anaclet C, Guhennec C, et al. The brain H3 receptor as a novel therapeutic target for vigilance and sleep-wake disorders. Biochem Pharmacol 2007;73:1157-1171 • Detailed work dealing with the effects of H3R antagonists in arousal. (Pubitemid 46413178)
43. Guo RX, Anaclet C, Roberts JC, et al. Differential effects of acute and repeat dosing with the H3 antagonist GSK189254 on the sleep-wake cycle and narcoleptic episodes in Ox-/- mice. Br J Pharmacol 2009;157:104-117
44. Lin JS, Dauvilliers Y, Arnulf I, et al. An inverse agonist of the histamine H3 receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients. Neurobiol Dis 2008;30:74-83
45. Ligneau X, Perrin D, Landais L, et al. BF2.649 [1-{3-[3-(4-Chlorophenyl) propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: preclinical pharmacology. J Pharmacol Exp Ther 2007;320:365-375 (Pubitemid 46025751)
46. A phase II randomized, double-blind, double-dummy, placebo and comparator-controlled, parallel group, multi-center study to investigate the safety and efficacy of a single dose of JNJ-17216498 administered to subjects with narcolepsy. Available from: http://www.clinicaltrials.gov
47. An open label, dose escalation study with a double blind randomised placebo controlled withdrawal to examine the effects of the histamine H3 antagonist GSK189254 in patients with narcolepsy. Available from: http://www.clinicaltrials.gov
48. Randomized, dose-finding study of BF 2.649 5, 10 20 and 40 mg/d in comparison to placebo in excessive daytime sleepiness in Parkinson's disease patients (PD). Available from: http://www.clinicaltrials.gov
49. Morimoto K, Fahnestock M, Racine RJ. Kindling and status epilepticus models of epilepsy: rewiring the brain. Prog Neurobiol 2004;73:1-60 (Pubitemid 38749090)
50. Tuomisto L, Tacke U. Is histamine an anticonvulsive inhibitory transmitter? Neuropharmacol 1986;25:955-958
51. Kamei C, Ishizawa K, Kakinoki H, Fukunaga M. Histaminergic mechanisms in amygdaloid-kindled seizures in rats. Epilepsy Res 1998;30:187-194 (Pubitemid 28273383)
52. Dai H, Fu Q, Shen Y, et al. The histamine H3 receptor antagonist clobenpropit enhances GABA release to protect against NMDA-induced excitotoxicity through the cAMP/protein kinase A pathway in cultured cortical neurons. Eur J Pharmacol 2007;563:117-123 (Pubitemid 46602226)
53. Yawata I, Tanaka K, Nakagawa Y, et al. Role of histaminergic neurons in development of epileptic seizures in EL mice. Brain Res Mol Brain Res 2004;132:13-17 (Pubitemid 39531347)
54. Vohora D, Pal SN, Pillai KK. Histamine and selective H3 receptor ligands: a possible role in the mechanism and management of epilepsy. Pharmacol Biochem Behav 2001;68:735-741 (Pubitemid 32411611)
55. Baron R, Schwarz K, Kleinert A, et al. Histamine-induced itch converts into pain in neuropathic hyperalgesia. Neuroreport 2001;12:3475-3478 (Pubitemid 33065481)
56. Moalem G, Tracey DJ. Immune and inflammatory mechanisms in neuropathic pain. Brain Res Rev 2006;51:240-264 (Pubitemid 43902971)
57. White FA, Jung H, Miller RJ. Chemokines and the pathophysiology of neuropathic pain. Proc Natl Acad Sci USA 2007;104:20151-20158
58. Medhurst SJ, Collins SD, Billinton A, et al. Novel histamine H3 receptor antagonists GSK 189254 and GSK 334429 are efficacious in surgically-induced and virally-induced rat models of neuropathic pain. Pain 2008;138:61-69 • H3R antagonists in acute and chronic pain models.
59. Cannon KE, Chazot PL, Hann V, et al. Immunohistochemical localization of histamine H3 receptors in rodent skin, dorsal root ganglia, superior cervical ganglia, and spinal cord: potential antinociceptive targets. Pain 2007;129:76-92 (Pubitemid 46551373)
60. Rouleau A, Garbarg M, Ligneau X, et al. Bioavailability, antinociceptive and antiinflammatory properties of BP 2-94, a histamine H3 receptor agonist prodrug. J Pharmacol Exp Ther 1997;281:1085-1094 (Pubitemid 27258364)
61. Rouleau A, Stark H, Schunack W, Schwartz JC. Anti-inflammatory and antinociceptive properties of BP-294, a histamine H3 receptor agonist prodrug. J Pharmacol Exp Ther 2000;295:219-225 (Pubitemid 30746084)
62. Fozard JR. BP-294 Ste Civile Bioprojet. Curr Opin Investig Drugs 2000;1:86-89
63. Cannon KE, Nalwalk JW, Stadel R, et al. Activation of spinal histamine H3 receptors inhibits mechanical nociception. Eur J Pharmacol 2003;470:139-147 (Pubitemid 36694469)
64. Smith FM, Haskelberg H, Tracey DJ, Moalem-Taylor G. Role of histamine H3 and H4 receptors in mechanical hyperalgesia following peripheral nerve injury. Neuroimmunomodulation 2007;14:317-325 (Pubitemid 351737859)
65. Farzin D, Asghari L, Nowrouzi M. Rodent antinociception following acute treatment with different histamine receptor agonists and antagonists. Pharmacol Biochem Behav 2002;72:751-760 (Pubitemid 34450874)
66. Coruzzi G, Adami M, Guaita E, et al. Antiinflammatory and antinociceptive effects of the selective histamine H4 receptor antagonists JNJ-7777120 and VUF 6002 in a rat model of carrageenan-induced acute inflammation. Eur J Pharmacol 2007;563:240-244 (Pubitemid 46602245)
67. Liu H, Altenbach RJ, Carr TL, et al. cis-4-(Piperazin-1-yl)-5,6,7a,8,9, 10,11, 11a-octahydrobenzofuro[2,3-h] quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia. J Med Chem 2008;51:7094-7098
68. Cowart MD, Altenbach RJ, Liu H, et al. Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models. J Med Chem 2008;51:6547-6557
69. Zampeli E, Tiligada E. The role of histamine H4 receptor in immune and inflammatory disorders. Br J Pharmacol 2009;157:24-33 •• Recent review covering the latest findings relating to the roles of the H4R in the immune system and inflammation.
70. Leurs R, Chazot PL, Shenton FC, et al. Molecular and biochemical pharmacology of the histamine H4 receptor. Br J Pharmacol 2009;157:14-23 •• Recent review covering the latest findings relating to H4R molecular and biochemical pharmacology.
71. Sander K, Kottke T, Proschak E, et al. Development of diaminopyrimidines as histamine H4 receptor ligands: virtual screening and scaffold optimization. XXXVIIIth Meeting of the European Histamine Research Society. Fulda, Germany 13 - 16 May 2009. O26
72. Jablonowski JA, Grice CA, Chai W, et al. The first potent and selective non-imidazole human histamine H4 receptor antagonists. J Med Chem 2003;46:3957-3960 (Pubitemid 37122442)
73. Kiss R, Kiss B, Konczol A, et al. Discovery of novel human histamine H4 receptor ligands by large-scale structure-based virtual screening. J Med Chem 2008;51:3145-3153 (Pubitemid 351821875)
74. Tanrikulu Y, Proschak E, Werner T, et al. Homology model adjustment and ligand screening with a pseudoreceptor of the human histamine H4 receptor. ChemMedChem 2009;4:820-827
75. Igel P, Schneider E, Schnell D, et al. NG-Acylated imidazolylpropylguanidines as potent histamine H4 receptor agonists: selectivity by variation of the NG-substituent. J Med Chem 2009;52:2623-2627
76. Thurmond RL, Gelfand EW, Dunford PJ. The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines. Nat Rev Drug Discov 2008;7:41-53
77. O'Reilly M, Alpert R, Jenkinson S, et al. Identification of a histamine H4 receptor on human eosinophils - role in eosinophil chemotaxis. J Recept Signal Transduct Res 2002;22:431-448 (Pubitemid 36169163)
78. Thurmond RL, Desai PJ, Dunford PJ, et al. A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties. J Pharmacol Exp Ther 2004;309:404-413 • Use of the selective H4R antagonist JNJ-7777120 to provide experimental evidence for the involvement of H4R in allergy and inflammation.
79. Hofstra CL, Desai PJ, Thurmond RL, Fung-Leung WP. Histamine H4 receptor mediates chemotaxis and calcium mobilization of mast cells. J Pharmacol Exp Ther 2003;305:1212-1221
80. Dunford PJ, O'Donnell N, Riley JP, et al. The histamine H4 receptor mediates allergic airway inflammation by regulating the activation of CD4+ T cells. J Immunol 2006;176:7062-7070 (Pubitemid 43787887)
81. Morgan RK, McAllister B, Cross L, et al. Histamine 4 receptor activation induces recruitment of FoxP3+ T cells and inhibits allergic asthma in a murine model. J Immunol 2007;178:8081-8089 (Pubitemid 46898080)
82. Dijkstra D, Leurs R, Chazot P, et al. Histamine downregulates monocyte CCL2 production through the histamine H4 receptor. J Allergy Clin Immunol 2007;120:300-307
83. Zampeli E, Thurmond RL, Tiligada E. The histamine H4 receptor antagonist JNJ-7777120 induces increases in the histamine content of the rat conjunctiva. Inflamm Res 2009;58:285-291
84. Yu S, Stahl E, Li Q, Ouyang A. Antigen inhalation induces mast cells and eosinophils infiltration in the guinea pig esophageal epithelium involving histamine-mediated pathway. Life Sci 2008;82:324-330
85. Bell JK, McQueen DS, Rees JL. Involvement of histamine H4 and H1 receptors in scratching induced by histamine receptor agonists in Balb C mice. Br J Pharmacol 2004;142:374-380
86. Bäumer W, Wendorff S, Gutzmer R, et al. Histamine H4 receptors modulate dendritic cell migration through skin: immunomodulatory role of histamine. Allergy 2008;63:1387-1394
87. Dunford PJ, Williams KN, Desai PJ, et al. Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus. J Allergy Clin Immunol 2007;119:176-183
88. Rossbach K, Wendorff S, Sander K, et al. Histamine H4 receptor antagonism reduces hapten-induced scratching behaviour but not inflammation. Exp Dermatol 2009;18:57-63
89. Grzybowska-Kowalczyk A, Wojtecka-Lukasik E, Maslinska D, et al. Distribution pattern of histamine H4 receptor in human synovial tissue from patients with rheumatoid arthritis. Inflamm Res 2007;56(Suppl 1):S59-60
90. Ikawa Y, Suzuki M, Shiono S, et al. Histamine H4 receptor expression in human synovial cells obtained from patients suffering from rheumatoid arthritis. Biol Pharm Bull 2005;28:2016-2018 (Pubitemid 41437104)
91. Ohki E, Suzuki M, Aoe T, et al. Expression of histamine H4 receptor in synovial cells from rheumatoid arthritic patients. Biol Pharm Bull 2007;30:2217-2220 (Pubitemid 350097065)
92. Grzybowska-Kowalczyk A, Maslinska D, Wojciechowska M, et al. Expression of histamine H4 receptor in human osteoarthritic synovial tissue. Inflamm Res 2008;57(Suppl 1):S63-4
93. Zampeli E, Thurmond RL, Tiligada E. Effect of the H4R antagonist JNJ7777120 on the cartilage histamine content in rats with adjuvant arthritis. Fund Clin Pharmacol 2008;22:S10
94. Kyriakidis K, Zampeli E, Tiligada E. Effect of the H4 receptor antagonist JNJ7777120 on histamine levels of peripheral blood vessels in rats with adjuvant arthritis. XXXVIIIth Meeting of the European Histamine Research Society. Fulda, Germany 13 - 16 May 2009. O28
95. Boer K, Helinger E, Helinger A, et al. Decreased expression of histamine H1 and H4 receptors suggests disturbance of local regulation in human colorectal tumours by histamine. Eur J Cell Biol 2008;87:227-236
96. Medina V, Cricco G, Nunez M, et al. Histamine-mediated signaling processes in human malignant mammary cells. Cancer Biol Ther 2006;5:1462-1471 (Pubitemid 46256614)
97. Medina V, Croci M, Crescenti E, et al. The role of histamine in human mammary carcinogenesis: H3 and H4 receptors as potential therapeutic targets for breast cancer treatment. Cancer Biol Ther 2008;7:28-35
98. Rivera ES, Massari N, Medina VA, et al. Histamine-mediated biological responses in WM35 human melanoma cells. XXXVIIIth Meeting of the European Histamine Research Society. Fulda, Germany 13 - 16 May 2009. P30
99. Davenas E, Rouleau A, Morisset S, Arrang JM. Autoregulation of McA-RH7777 hepatoma cell proliferation by histamine H3 receptors. J Pharmacol Exp Ther 2008;326:406-413